Archives of Pharmacal Research

, Volume 32, Issue 9, pp 1309–1315

Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells

Authors

  • Yanyan Qiao
    • Department of Reproductive Medicine, Basic Medical CollegeCapital Medical University
  • Jinyan Cao
    • Department of ZoologyNorth Carolina State University
  • Liangqun Xie
    • Department of Reproductive Medicine, Basic Medical CollegeCapital Medical University
    • Department of Reproductive Medicine, Basic Medical CollegeCapital Medical University
Research Articles Drug Actions

DOI: 10.1007/s12272-009-1917-3

Cite this article as:
Qiao, Y., Cao, J., Xie, L. et al. Arch. Pharm. Res. (2009) 32: 1309. doi:10.1007/s12272-009-1917-3

Abstract

EGCG [(-)-epigallocatechin-3-gallate] has shown its antitumor ability and perhaps a potential regimen for cancer patients. The goal of this study was to investigate the effect of EGCG on human papilloma virus (HPV) positive cervical cancer cell lines. EGCG inhibited the growth of CaSki (HPV16 positive) and HeLa (HPV18 positive) cells in a time- and concentration-dependent manner. Cell cycle arrest and apoptosis were observed in two cell lines after EGCG exposure. More importantly, we focused on EGCG regulation ability on pivotal genes involved in cervical cancer: viral oncogenes E6/E7, estrogen receptor (ER) and aromatase. Our results suggested that EGCG may be suitable for prevention and treatment of cervical cancer.

Key words

EGCGCervical cancerHPVERAromatase
Download to read the full article text

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2009